Despite the controversy surrounding GLP-1 receptor expression in hepatic tissue, GLP-1 receptor agonists (GLP-1RA), have been shown to affect dysregulated pathways of metabolic disorders and, therefore, have become a promising therapeutic option. Here, GLP1R is linked to Other metabolic disease.